Zymeworks presents six posters at AACR highlighting advancements in antibody-drug conjugates and T cell engagers, including ZW209's promise in lung cancer. Zymeworks Inc. announced the presentation of ...
Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission expected in 1H-2026 VANCOUVER, British Columbia, April 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc.
Nomination of ZW209, a novel trispecific T cell engager, as fifth development candidate in the Company's solid tumor portfolio Expansion into autoimmune and inflammatory diseases (AIID) and hematology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results